Search Thermo Fisher Scientific
- Order Status
- Quick Order
-
Don't have an account ? Create Account
Gibco Cell Therapy Bioprocessing Reagents
Gibco CTS Dynabeads magnetic beads are a trusted technology for the isolation, activation, and/or expansion of T-cells ex vivo. Whether working with polyclonal T-cells, antigen-specific T-cells, gene-modified T-cells, regulatory T-cells, or other T-cell subtypes, CTS Dynabeads magnetic beads enable the recovery of T-cells with properties comparable to in vivo–activated T-cells.
Our Gibco CTS Detachable Dynabeads beads possess a proprietary active release mechanism—the first of its kind for GMP, clinical trial, and commercial manufacturing use. These new offerings are intended for use with the CTS DynaCellect system to achieve its full range of benefits. With its active release mechanism and high specificity, our CTS Detachable Dynabeads platform allows for significant flexibility and scalability of manufacturing processes that vary widely from one therapy to another. Its performance exhibits consistent and optimal isolation, activation, and purity of target T-cell populations while addressing the biological variability that cell therapy manufacturers are facing.
The CTS Detachable Dynabeads beads are based on our existing paramagnetic bead technology, but conjugated to highly specific, single-domain VHH antibodies that target specific clusters of differentiation (CD) markers for isolation and/or activation. After isolation of target immune cells and magnetic separation in the CTS DynaCellect system, the Gibco CTS Detachable Dynabeads Release Buffer is used to actively detach target cells from the CTS Dynabeads beads through a competitive binding mechanism. This flexible and scalable platform technology enables optimal isolation, activation, and purity, yield, desired phenotype, cell viability of subpopulations of T-cells.
CTS Detachable Dynabeads CD3/CD28
Gibco CTS Detachable Dynabeads CD3/CD28 magnetic beads are a flexible and scalable platform technology that helps enable isolation and activation in one step while possessing a differentiating active release mechanism. CTS Detachable Dynabeads CD3/CD28 has been found to be comparable to the passive detachable Dynabeads in IL-2 expression, activation marker profile, cytokine release panel, and cell proliferation levels. The key difference is the added release functionality to address biological variability and helps provide users with flexibility in their manufacturing process.
Click to enlarge
Figure 1A
Click to enlarge
Figure 1B
Figure 1. CTS Detachable Dynabeads CD3/CD28 induces similar expression of activation markers for A) CD69 and B) CD25 as the passive release CTS Dynabeads CD3/CD28. On days 2 and 3 post-activation, 94% to 98% of T-cells are expressing the CD25 activation marker, respectively.
Ordering information
CTS Dynabeads CD3/CD28
Used in more than 100 clinical trials, Gibco CTS Dynabeads magnetic beads are a trusted technology for the isolation, activation, and/or expansion of T-cells ex vivo. Whether working with polyclonal T-cells, antigen-specific T-cells, gene-modified T-cells, regulatory T-cells, or other T-cell subtypes, CTS Dynabeads magnetic beads enable the recovery of T-cells with properties comparable to in vivo–activated T-cells. This one-step process of simultaneous T-cell isolation and activation yields pure and uniformly activated T-cells.
Click to enlarge
Figure 2. Activated T-cells typically expand >100-fold in 10 days. (A, B) Isolated and activated T-cells were expanded for up to 10 days, and both CD4+ and CD8+ T-cells proliferated. (C, D) On day 10 post-activation, there were mainly CD45RA+/– CD127+/– CD28+ CD62L+ cells with low PD-1 expression.
Ordering information
CTS Treg Xpander
Gibco CTS Dynabeads Treg Xpander provides an optimized activation signal for activation and expansion of Regulatory T-cells (Tregs) and yields high-fold expansion of suppressive Tregs with a stable Treg phenotype, which is essential for use of Tregs in clinical applications.
Key features
- Scalable technology for robust activation and expansion of Tregs
- Clinically relevant numbers of Tregs with >800-fold expansion after two stimulations
- Aseptically manufactured and ready for clinical trials and commercial manufacturing
- Maintained Treg phenotype (FoxP3) and suppressive function
- Drug Master File available
- Conformity with cGMP guidelines
Click to enlarge
Figure 3.Optimized activation signal expands Tregs to clinically relevant numbers. Flow sorted regulatory T-cells were expanded with CTS Dynabeads Treg Xpander, CTS Dynabeads CD3/CD28 or competitor technology for 14 days with restimulation at day 9.
Click to enlarge
Figure 4. Optimized activation signal expands Tregs with high suppressive potential. Magnetically isolated regulatory T-cells were expanded three times with CTS Dynabeads Treg Xpander for 14 days. Expanded Tregs are highly suppressive.
Ordering information
Dynabeads Human T-Expander CD3/CD28
Dynabeads Human T-Expander CD3/CD28, the research-grade version of CTS Dynabead CD3/CD28, is intended for separation, activation, and expansion of human T-cells. Containing the same amount and ratio of antibodies from the same clones as CTS Dynabeads CD3/CD28, Dynabeads Human T-Expander CD3/CD28 are intended for small-scale pre-clinical research. Dynabeads Human T-Expander CD3/CD28 offers a simple method for the activation and expansion of T-cells that does not require antigen presenting cells or antigen.
Ordering information
CTS Detachable Dynabeads CD3/CD28
Gibco CTS Detachable Dynabeads CD3/CD28 magnetic beads are a flexible and scalable platform technology that helps enable isolation and activation in one step while possessing a differentiating active release mechanism. CTS Detachable Dynabeads CD3/CD28 has been found to be comparable to the passive detachable Dynabeads in IL-2 expression, activation marker profile, cytokine release panel, and cell proliferation levels. The key difference is the added release functionality to address biological variability and helps provide users with flexibility in their manufacturing process.
Click to enlarge
Figure 1A
Click to enlarge
Figure 1B
Figure 1. CTS Detachable Dynabeads CD3/CD28 induces similar expression of activation markers for A) CD69 and B) CD25 as the passive release CTS Dynabeads CD3/CD28. On days 2 and 3 post-activation, 94% to 98% of T-cells are expressing the CD25 activation marker, respectively.
Ordering information
CTS Dynabeads CD3/CD28
Used in more than 100 clinical trials, Gibco CTS Dynabeads magnetic beads are a trusted technology for the isolation, activation, and/or expansion of T-cells ex vivo. Whether working with polyclonal T-cells, antigen-specific T-cells, gene-modified T-cells, regulatory T-cells, or other T-cell subtypes, CTS Dynabeads magnetic beads enable the recovery of T-cells with properties comparable to in vivo–activated T-cells. This one-step process of simultaneous T-cell isolation and activation yields pure and uniformly activated T-cells.
Click to enlarge
Figure 2. Activated T-cells typically expand >100-fold in 10 days. (A, B) Isolated and activated T-cells were expanded for up to 10 days, and both CD4+ and CD8+ T-cells proliferated. (C, D) On day 10 post-activation, there were mainly CD45RA+/– CD127+/– CD28+ CD62L+ cells with low PD-1 expression.
Ordering information
CTS Treg Xpander
Gibco CTS Dynabeads Treg Xpander provides an optimized activation signal for activation and expansion of Regulatory T-cells (Tregs) and yields high-fold expansion of suppressive Tregs with a stable Treg phenotype, which is essential for use of Tregs in clinical applications.
Key features
- Scalable technology for robust activation and expansion of Tregs
- Clinically relevant numbers of Tregs with >800-fold expansion after two stimulations
- Aseptically manufactured and ready for clinical trials and commercial manufacturing
- Maintained Treg phenotype (FoxP3) and suppressive function
- Drug Master File available
- Conformity with cGMP guidelines
Click to enlarge
Figure 3.Optimized activation signal expands Tregs to clinically relevant numbers. Flow sorted regulatory T-cells were expanded with CTS Dynabeads Treg Xpander, CTS Dynabeads CD3/CD28 or competitor technology for 14 days with restimulation at day 9.
Click to enlarge
Figure 4. Optimized activation signal expands Tregs with high suppressive potential. Magnetically isolated regulatory T-cells were expanded three times with CTS Dynabeads Treg Xpander for 14 days. Expanded Tregs are highly suppressive.
Ordering information
Dynabeads Human T-Expander CD3/CD28
Dynabeads Human T-Expander CD3/CD28, the research-grade version of CTS Dynabead CD3/CD28, is intended for separation, activation, and expansion of human T-cells. Containing the same amount and ratio of antibodies from the same clones as CTS Dynabeads CD3/CD28, Dynabeads Human T-Expander CD3/CD28 are intended for small-scale pre-clinical research. Dynabeads Human T-Expander CD3/CD28 offers a simple method for the activation and expansion of T-cells that does not require antigen presenting cells or antigen.
Ordering information
Related Resources
Application notes
Flyers
Bioprocessing resources
Access a targeted collection of scientific application notes, case studies, posters, white papers and more for bioprocessing:
Support
Events & Webinars
Intended use of the products mentioned on this page vary. For specific intended use statements please refer to the product label.